Last updated: October 5, 2026
KOMBIGLYZE XR is AstraZeneca's extended-release fixed-dose combination of saxagliptin and metformin hydrochloride for adults with type 2 diabetes. Its commercial trajectory has been negative because the DPP-4 inhibitor class has lost share to GLP-1 receptor agonists and SGLT2 inhibitors, while generic metformin and lower-priced DPP-4 alternatives have compressed pricing.
AstraZeneca does not report KOMBIGLYZE XR revenue separately. Financial analysis therefore relies on the broader Onglyza saxagliptin franchise, product-level prescription trends, regulatory records, and class performance. The franchise has shifted from a growth product to a mature, declining asset with limited strategic importance.
What is KOMBIGLYZE XR and how does it work?
KOMBIGLYZE XR combines two established type 2 diabetes mechanisms:
| Component |
Mechanism |
Commercial role |
| Saxagliptin |
DPP-4 inhibition, increasing incretin activity and glucose-dependent insulin release |
Branded, patent-protected component |
| Metformin extended release |
Reduces hepatic glucose production and improves insulin sensitivity |
Low-cost generic backbone |
| Dosage form |
Once-daily extended-release tablet |
Adherence and convenience advantage |
The FDA approved KOMBIGLYZE XR in 2010 as an adjunct to diet and exercise for adults with type 2 diabetes. The product is available in multiple saxagliptin/metformin strengths, including 5 mg/500 mg, 5 mg/1,000 mg, 2.5 mg/1,000 mg and 2.5 mg/500 mg presentations, subject to the current label and market availability.[1]
The product's commercial logic was straightforward: combine a branded DPP-4 inhibitor with a widely used metformin formulation and offer a single-pill alternative to separate tablets. That positioning became less effective as diabetes treatment moved toward cardiovascular and weight-loss outcomes.
How has the KOMBIGLYZE XR market changed?
KOMBIGLYZE XR competes in a mature diabetes market with substantial therapeutic substitution. The main market pressures are:
- Greater use of GLP-1 receptor agonists for weight reduction and cardiovascular risk management.
- Greater use of SGLT2 inhibitors for heart failure and chronic kidney disease benefits.
- Generic competition for sitagliptin, linagliptin and saxagliptin products.
- Payer preference for lower-cost combinations.
- Limited clinical differentiation between DPP-4 inhibitors in glucose lowering.
DPP-4 inhibitors remain useful for patients who need oral therapy, have a low hypoglycemia risk, or cannot tolerate GLP-1 receptor agonists. Their limitations are commercial as well as clinical. They generally produce less weight loss than GLP-1 therapies, do not deliver the same renal or heart-failure positioning as SGLT2 inhibitors, and have modest effects on glycated hemoglobin.
How does KOMBIGLYZE XR compare with competing diabetes drugs?
| Product or class |
Main advantage |
Main competitive pressure on KOMBIGLYZE XR |
| Januvia and Janumet |
Large installed base and established sitagliptin data |
Direct DPP-4 competition and generic erosion |
| Tradjenta and Jentadueto |
DPP-4 option with renal-dosing convenience |
Payer substitution and class maturity |
| Farxiga and Jardiance |
Heart-failure and renal-risk positioning |
Shift in prescribing beyond glucose control |
| Ozempic, Rybelsus and Trulicity |
Strong weight-loss and cardiometabolic positioning |
Reduced use of DPP-4 therapy in higher-risk patients |
| Generic metformin combinations |
Low price |
Weakens the premium for a branded fixed-dose tablet |
| Insulin and sulfonylureas |
Low acquisition cost |
Continued use in price-sensitive markets |
KOMBIGLYZE XR's most defensible commercial niche is a once-daily oral combination for patients who remain appropriate for DPP-4 therapy and metformin. That niche is narrower than the original product opportunity.
What is the financial trajectory of KOMBIGLYZE XR?
KOMBIGLYZE XR revenue is not separately disclosed in AstraZeneca's annual reports. AstraZeneca generally reports the saxagliptin franchise through Onglyza-related sales and does not provide a standalone KOMBIGLYZE XR revenue line. The product's financial trajectory must therefore be assessed through franchise-level disclosures.
Saxagliptin franchise trajectory
| Period |
Financial direction |
Principal drivers |
| 2010-2014 |
Expansion |
New-product adoption, DPP-4 class growth, combination prescribing |
| 2015-2017 |
Maturity |
Increased competition from Januvia, Tradjenta and other oral agents |
| 2018-2020 |
Decline |
GLP-1 and SGLT2 displacement, payer pressure, safety-related prescribing caution |
| 2021-2023 |
Accelerated erosion |
Generic entry across the DPP-4 market, lower prices and reduced class growth |
| 2024 onward |
Residual or declining revenue |
Mature branded product, generic substitution and limited innovation value |
AstraZeneca's broader diabetes portfolio has generated substantial revenue, but the company's reported growth has increasingly come from newer products rather than saxagliptin. Farxiga, in particular, has benefited from expanded heart-failure and chronic-kidney-disease use, while saxagliptin has remained tied to the older glucose-lowering segment.[2]
KOMBIGLYZE XR likely represented a smaller portion of the franchise than standalone Onglyza because fixed-dose combination products compete against inexpensive generic metformin and separate DPP-4 tablets. Its value was primarily commercial convenience, not a distinct mechanism or clinical outcome benefit.
What factors reduced KOMBIGLYZE XR sales?
DPP-4 class displacement
The strongest pressure came from treatment guidelines and prescribing behavior that increasingly prioritize cardiovascular, renal and weight outcomes. DPP-4 inhibitors reduce glucose without substantial hypoglycemia or weight gain, but they do not match the outcome profile of newer therapies for many high-risk patients.
Saxagliptin heart-failure warning
The SAVOR-TIMI 53 cardiovascular outcomes trial reported an increased risk of hospitalization for heart failure with saxagliptin. The FDA added a heart-failure warning to saxagliptin-containing products, including KOMBIGLYZE XR.[3]
The warning did not remove the product from the market, but it weakened its position in patients with heart failure or elevated heart-failure risk. Prescribers could choose other DPP-4 agents or move patients to an SGLT2 inhibitor when heart-failure protection was clinically relevant.
Generic metformin economics
Metformin is inexpensive and widely available in generic form. A fixed-dose combination must therefore justify its price through adherence, reduced pill burden or payer coverage. Once saxagliptin lost exclusivity, the premium associated with the combination became more difficult to defend.
Retail and payer substitution
Managed-care formularies can encourage substitution among DPP-4 products. A payer may prefer a lower-net-cost sitagliptin, linagliptin or generic saxagliptin product, even when the clinical differences between products are limited. Combination products can also face separate-tablet substitution if the fixed-dose tablet carries a higher net cost.
When did KOMBIGLYZE XR lose exclusivity?
KOMBIGLYZE XR's regulatory and patent protection should be separated.
FDA regulatory exclusivity
The product was approved in 2010. New chemical entity exclusivity did not apply in the same manner to the fixed-dose combination because the active ingredients, saxagliptin and metformin, were previously known. Combination products can receive other forms of regulatory exclusivity when supported by qualifying clinical investigations, but these periods are shorter and product-specific.
The practical commercial protection came from patents covering saxagliptin, pharmaceutical compositions, formulations and combination products rather than from long-term regulatory exclusivity.
Patent protection
Saxagliptin's core compound protection was associated with U.S. Patent No. 6,395,767, assigned to Bristol-Myers Squibb and later relevant to AstraZeneca's saxagliptin franchise. The core compound patent expired around the beginning of the 2020s, including any applicable pediatric extension.[4]
KOMBIGLYZE XR also depended on formulation and combination patents listed in FDA's Orange Book. Those patents could create different expiration dates from the core saxagliptin patent. The Orange Book is the controlling public source for currently listed patents, expiration dates and pediatric extensions for the approved product.[5]
The commercial consequence was a staggered loss of protection. Even where a formulation patent remained relevant, generic applicants could challenge individual patents through Paragraph IV certifications or pursue non-infringing formulations.
What is the Orange Book status of KOMBIGLYZE XR?
The Orange Book identifies approved drug products, therapeutic equivalence information and patents submitted by the NDA holder. For KOMBIGLYZE XR, the relevant regulatory questions are:
- Whether the branded NDA remains active.
- Which patents remain listed against the product.
- Whether an Orange Book-listed patent has expired.
- Whether a generic applicant has filed a Paragraph IV certification.
- Whether the generic product has an AB rating or another therapeutic-equivalence designation.
- Whether AstraZeneca has discontinued commercial distribution while the NDA remains active.
A branded product can lose practical exclusivity before every listed patent expires. Generic applicants may avoid a formulation patent, challenge its validity or negotiate a settlement allowing an earlier launch.
Which companies are challenging KOMBIGLYZE XR?
Public ANDA litigation and Paragraph IV activity for saxagliptin/metformin extended-release products should be evaluated through FDA, PACER and federal district court records. The relevant competitive set includes generic manufacturers that have pursued saxagliptin, metformin extended-release or related fixed-dose combinations.
The principal risks are not limited to a single litigation case. Generic entry can occur through:
- A successful Paragraph IV challenge.
- Expiration of the relevant patent without litigation.
- A settlement with an agreed launch date.
- A non-infringing formulation.
- Authorized generic or licensed supply arrangements.
Because AstraZeneca has not reported KOMBIGLYZE XR revenue separately, any litigation settlement would affect the broader saxagliptin franchise rather than a separately disclosed financial line.
What generic launch risks exist?
Base-case scenario
The base case is continued revenue erosion through generic substitution and reduced use of the DPP-4 class. The product retains residual demand in markets where oral therapy, once-daily dosing and low hypoglycemia risk remain important.
Downside scenario
A broad generic launch for saxagliptin/metformin extended release would pressure both volume and price. Payers could move patients from branded KOMBIGLYZE XR to generic combinations or separate generic tablets. Net sales would likely fall faster than prescriptions because rebates and formulary concessions would increase.
Limited-upside scenario
A temporary shortage, supply disruption or payer preference for a specific fixed-dose combination could support short-term branded demand. That would not change the long-term structure of the market.
Does KOMBIGLYZE XR face biosimilar risk?
No. KOMBIGLYZE XR is a small-molecule tablet, not a biologic. It faces generic-drug risk through the ANDA pathway rather than biosimilar competition under the Public Health Service Act.
The generic risk is structurally stronger than biosimilar risk because an approved generic can be substituted at the pharmacy when it receives the appropriate therapeutic-equivalence designation and state substitution rules permit it.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are moderate. The product requires:
- Saxagliptin active pharmaceutical ingredient.
- Metformin hydrochloride extended-release technology.
- Controlled-release tablet manufacturing.
- Stability and dissolution performance across multiple strengths.
- Bioequivalence testing for the fixed-dose product.
The extended-release formulation creates more technical complexity than an immediate-release tablet. The barrier is still lower than for sterile injectables, inhaled products or biologics. Once formulation patents expire or are successfully designed around, multiple manufacturers can compete.
The strongest remaining commercial barriers are regulatory filing costs, manufacturing validation, distribution, pharmacy substitution and payer access. They are not sufficient to preserve a durable branded premium after broad generic entry.
What is the competitive outlook for AstraZeneca?
AstraZeneca's diabetes strategy has moved toward products with broader cardiometabolic value. Farxiga has a stronger growth profile because its approved uses extend beyond glycemic control. Saxagliptin products occupy a mature segment and require less strategic investment.
The company has an incentive to preserve regulatory supply and selected market access while allocating commercial resources to faster-growing medicines. That reduces the likelihood of major new investment in KOMBIGLYZE XR marketing, lifecycle expansion or formulation innovation.
Key Takeaways
- KOMBIGLYZE XR combines saxagliptin and extended-release metformin for type 2 diabetes.
- AstraZeneca does not separately disclose KOMBIGLYZE XR revenue.
- The product's financial trajectory is best measured through the declining saxagliptin/Onglyza franchise.
- GLP-1 receptor agonists and SGLT2 inhibitors have reduced DPP-4 prescribing growth.
- The saxagliptin heart-failure warning weakened the product's use in higher-risk patients.
- Core saxagliptin protection expired around the beginning of the 2020s, with formulation patents potentially extending protection for specific presentations.
- KOMBIGLYZE XR faces generic, not biosimilar, competition.
- Its remaining value is concentrated in oral convenience, established clinical use and residual payer coverage.
- AstraZeneca's higher-growth diabetes economics are now concentrated in Farxiga rather than saxagliptin combinations.
FAQs About KOMBIGLYZE XR Market and Financial Outlook
Is KOMBIGLYZE XR still commercially important to AstraZeneca?
No. It remains a marketed diabetes product, but it is not a major growth driver. AstraZeneca's diabetes growth has shifted toward Farxiga and other higher-value products.
Is KOMBIGLYZE XR more effective than Janumet?
Both are DPP-4 inhibitor/metformin combinations. KOMBIGLYZE XR contains saxagliptin, while Janumet contains sitagliptin. Comparative selection depends on renal function, heart-failure considerations, formulary status, tolerability and price.
Can KOMBIGLYZE XR cause heart failure?
Saxagliptin-containing products carry a heart-failure warning based on increased hospitalization observed in a cardiovascular outcomes trial. The risk-benefit assessment is particularly relevant for patients with existing heart failure or elevated risk.[3]
What replaced KOMBIGLYZE XR in newer diabetes treatment strategies?
For patients needing stronger glucose lowering, weight reduction or cardiovascular and renal benefits, clinicians may consider GLP-1 receptor agonists or SGLT2 inhibitors. Metformin remains a common foundation where appropriate.
Is KOMBIGLYZE XR likely to be discontinued?
Commercial discontinuation is possible if branded demand becomes uneconomic, but regulatory discontinuation and market withdrawal are separate events. Generic availability can preserve the active ingredients even if branded distribution declines.
References
- U.S. Food and Drug Administration. (2010). KOMBIGLYZE XR prescribing information. FDA.
- AstraZeneca PLC. (2015-2023). Annual reports and Form 20-F filings. AstraZeneca.
- U.S. Food and Drug Administration. (2016). FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. FDA Drug Safety Communication.
- U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,395,767, compounds useful as dipeptidyl peptidase-IV inhibitors. USPTO.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
